Oncology

AstraZeneca offloads headache drug Zomig to Grünenthal to raise $300M cash AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company continues to struggle and so will sell yet another asset to raise cash while CEO Pascal Soriot works to right the ship. The U.K drugmaker today said that it has a deal to sell Germany’s Grünenthal rights to its migraine treatment Zomig for all markets outside of Japan. AZ will get $200 million when the deal is done and up to $102 million in additional payments if targets are hit. The arrangement includes rights to the drug in the U.S. where it has been licen...